ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Comparing Two Treatments for Infants With Hydrocephalus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00652470
Recruitment Status : Active, not recruiting
First Posted : April 3, 2008
Last Update Posted : April 25, 2017
Sponsor:
Collaborators:
The International Study Group for Neuroendoscopy (ISGNE)
The International Society for Pediatric Neurosurgery
Information provided by (Responsible Party):
Abhaya Kulkarni, The Hospital for Sick Children

March 31, 2008
April 3, 2008
April 25, 2017
September 2005
December 2018   (Final data collection date for primary outcome measure)
Health Status Outcome as measured by the Health Utilities Index - 2 [ Time Frame: At 5 years of age ]
Same as current
Complete list of historical versions of study NCT00652470 on ClinicalTrials.gov Archive Site
  • Death [ Time Frame: Duration of the Study ]
  • Neurodevelopment as measured by the Denver Developmental Screening Test [ Time Frame: Up to 3 years of Age ]
  • Health status outcome using the Hydrocephalus Outcome Questionnaire [ Time Frame: At 5 years of Age ]
  • In-depth Evaluation of Neurodevelopment, Functioning and Intelligence, as mesured by the Weschler Intelligence Scale for Children or Weschler Preschool and Primary Scale of Intelligence [ Time Frame: At 5 years of Age ]
  • Number of Subsequent Hydrocephalus-Related Operations [ Time Frame: Duration of the Study ]
  • Surgical Morbidity [ Time Frame: Duration of the Study ]
  • Incidence of failure of initial intervention [ Time Frame: Duration of the Study ]
  • Hospitalization Time [ Time Frame: 5 years post-operation ]
  • Need for repeat radiological scans [ Time Frame: Duration of the Study ]
  • Complications such as CNS infection, focal neurological deficit, significant hemorrhage, seizures requiring medication [ Time Frame: Duration of the Study ]
  • Ventricular size and the existence of flow void (ETV group)assessed through radiological evaluation [ Time Frame: 3 years of age ]
Same as current
Not Provided
Not Provided
 
A Study Comparing Two Treatments for Infants With Hydrocephalus
International Infant Hydrocephalus Study: A Multicentre, Prospective Study
The purpose of this study is to study whether infants with triventricular hydrocephalus (TVH) have a better long-term outcome at 5 years when they are treated with a new procedure, endoscopic third ventriculostomy (ETV), than infants treated with the more traditional treatment, insertion of a cerebrospinal fluid (CSF) shunt.

TVH is a relatively uncommon condition in infants, in which CSF accumulates in the brain's ventricles due to a blockage in outflow at the level of cerebral aqueduct. This can cause increased intracranial pressure, with adverse effect on brain development. The causes of this include congenital aqueductal stensois or acquired aqueductal stenosis from previous brain hemorrhage or infection.

TVH is currently treated through one of the following two approaches:

  • Extra-cranial CSF diversion through ventricular shunts. Extra-cranial shunting has been the standard approach over the past few decades, since functional shunts were first developed and inserted successfully.
  • Intra-cranial internal CSF diversion using endoscopic techniques. The principles of internal diversion were clear from the time neurosurgeons first understood the nature of hydrocephalus. However, internal diversion was never really practical or successful on a large scale until the more recent development of neuroendoscopy. There is currently a revived interest in diversionary hydrocephalus treatment through neuroendoscopic surgical techniques, with the primary focus on endoscopic third ventriculostomy (ETV).
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Hydrocephalus
  • Procedure: Endoscopic Third Ventriculostomy
    A standard frontal burr hole will be made and an endoscopic camera used to visualize the floor of the third ventricle. A ventriculostomy will be created in the floor of the third using the surgeon's own preferred method of perforation.
  • Procedure: CSF Shunt Insertion
    The procedure involves creating a burr hole in the frontal or occipital regions and cannulating the ventricle with a silastic catheter. This is then attached to a valve mechanism and distal silastic tubing which runs subcutaneously in the peritoneal cavity.
  • Active Comparator: ETV
    Intervention: Procedure: Endoscopic Third Ventriculostomy
  • Active Comparator: CSF Shunt
    Intervention: Procedure: CSF Shunt Insertion

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
182
Same as current
December 2019
December 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Symptomatic TVH requiring treatment.
  • No previous treatment for TVH
  • Under 24 months of age at time of surgery
  • Full-term pregnancy (>36 weeks)
  • Mandatory pre-operative MRI that includes mid-sagittal T1 & T2 scans which show: Tri-ventricular pattern of hydrocephalus; proof of no flow through aqueduct; presence of CSF collection over the convexity and/or inter-hemispheric fissure is acceptable; configuration of third ventricle floor could vary; deformed tectal plate is acceptable; posterior fossa fluid collections may be included as long as: aqueduct is closed; vermis preserved (complete Dandy Walker Syndrome excluded); questionable flow in aqueduct acceptable as long as TVH exists
  • History or suggestion of intra-ventricular bleed (intra-uterine or post-natal) or intracranial infection qualifies (excluding intraventricular hemorrhage of prematurity).
  • Ability to participate in followup for at least 5 years

Exclusion Criteria:

  • Open Spina Bifida
  • Complete Dandy Walker syndrome (vermian agenesis / dysgenesis)
  • Prematurity
  • Perinatal asphyxia
  • Severe dysmorphic anatomical features or known chromos (e.g. agenesis of corpus callosum, heterotopias, large cysts)
  • intracranial tumor
Sexes Eligible for Study: All
up to 24 Months   (Child)
No
Contact information is only displayed when the study is recruiting subjects
Argentina,   Brazil,   Canada,   Germany,   Hungary,   India,   Israel,   Italy,   Netherlands,   Poland,   Russian Federation,   Serbia,   Spain,   Turkey,   United Kingdom,   United States
Former Serbia and Montenegro
 
NCT00652470
1000007601
Yes
Not Provided
Not Provided
Abhaya Kulkarni, The Hospital for Sick Children
The Hospital for Sick Children
  • The International Study Group for Neuroendoscopy (ISGNE)
  • The International Society for Pediatric Neurosurgery
Principal Investigator: Abhaya Kulkarni, MD The Hospital for Sick Children, Toronto Canada
Principal Investigator: Shlomi Constantini, MD Dana Children's Hospital, Tel Aviv Medical Center
Principal Investigator: Spyros Sgouros, MD Birmingham Children's Hospital
The Hospital for Sick Children
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP